Synopsis
Differential Target MultiplexedTM spinal cord stimulation (SCS) is an established therapy that has shown superior back pain relief to traditional SCS.1 This study evaluates efficacy, device longevity, and recharge requirements of a reduced DTMTM derivative in patients with severe back and leg pain to understand opportunities to tailor therapy based on patient profiles and estimate device longevity and recharge requirements. Subjects were trialed with the DTMTM derivative and those who reported ≥50% improvement in overall pain were eligible for implant. Implanted subjects have reported therapy satisfaction and improved quality of life through 3-months and sustained overall pain relief through 6-months.
Disclosures
This study was funded by Medtronic.
K. Amirdelfan reports SAB at Nevro, Medtronic, and Nalu, consulting fees from Biotronik, Nalu, Nevro, Saluda, and Medtronic, research grants to institution from Nevro, Biotronik, and reports minor options at Nalu; M. Esposito reports SAB and consulting fees from Abbott, Biotronik, Boston Scientific, Flowonix, Inspan, Medtronic, Nevro, and Stimwave; M. Fishman reports research grants to institution from Abbott, Biotronik, Boston Scientific, Medtronic, Nalu Medical, SGX Medical, and Thermaquil, consulting fees from Abbott, Biotronik, Medtronic, and Nevro, faculty appointment with Abbott and Medtronic, and stock/stock options at Celeri Health, and Thermaquil; K. Gatzinsky reports consultancy (Teaching/training) at Medtronic, Boston Scientific, Abbott, Nevro, and SAB at Medtronic and Boston Scientific;. P.K. Grewal reports SAB at Medtronic; R. Justiz reports consulting fees from Medtronic; J.W. Kallewaard reports SAB at Abbott, Medtronic, Saluda and Boston Scientific; D. Provenzano reports consulting fees from Avanos, Boston Scientific, Medtronic, Nevro, SI Bone, and Wise, and research grants to institution from Avanos, Boston Scientific, Medtronic, Nevro, Stimgenics, and Abbott; T. White reports consulting fees from Medtronic; T. Bromberg reports relationships with Medtronic and Saluda; A. Calodney reports relationships with Boston Scientific, Medtronic, Nevro, and PainTeq; T. Schmidt reports relationships with Boston Scientific and Medtronic; J. Peacock and B. Shah report nothing to disclose; L. Davies, K. Noel, A. Cleland, M. LaRue, and C. Porritt are all employees of Medtronic.
Author(s):
- Lachlan Davies, BSc, Sr. Clinical Research Manager, Evidence Strategy and Therapy Development, Medtronic
- Jeffrey Peacock, MD, Novant Health, Pain Management
- Dr. David Provenzano, MD, President, Pain Diagnostics and Interventional Care
- Michael Fishman, MD, MBA, Anesthesiologist and Interventional Pain Medicine Specialist, Center for Interventional Pain and Spine
- Dr. Kasra Amirdelfan, MD, Interventional Pain Management Physician, IPM Medical Group
- Todd Bromberg, MD, Delaware Valley Pain and Spine Institute, Neurology
- Todd Schmidt, MD, Goodman Campbell Brain and Spine, Interventional Pain Management
- Thomas White, MD, Spritz Center for Pain, Pain Management
- Prabhdeep Grewal, MD, TSAOG Orthopaedics
- Rafael Justiz, MD, Pain Medicine Specialist, Oklahoma Pain Physicians
- Dr. Aaron K. Calodney, MD, DABA, FASA, FIPP, ABIPP, Director of Clinical Research, Precision Spine Care
- Amr El-Naggar, MD, FACS, DREZ One, Pain Management
- Dr. Binit Shah, MD, Pain Medicine Specialist, Carolinas Pain Center
- Dr. Michael Esposito, MD, Interventional Pain Management Physician, Florida Pain Institute
- Kliment Gatzinsky, MD, PhD, Sahlgrenska University Hospital, Department of Neurosurgery
- Jan Willem Kalleward, MD, Rijnstate Hospital, Anesthesiology and Pain Management
- Kate Noel, Biostatistician, Medtronic
- Andrew Cleland, MD, Principal Scientist, Medtronic
- Maddie LaRue
- Celeste Porritt, Principal Clinical Research Specialist, Medtronic
| Display Label | Action |
|---|---|
| 12_Davies - A Prospective Multi-Center Study | Download Abstract |
| 12_Davies Poster - A Prospective Multi-Center Study | Download Poster |